In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice

Koji Kabaya, Hiromichi Akahori, Kazunori Shibuya, Yuko Nitta, Masumi Ida, Masaru Kusaka, Takashi Kato, Hiroshi Miyazaki

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human thrombopoietin modified with polyethylene glycol, were investigated in normal Balb/c mice. PEG-rHuMGDF was more potent in producing platelets and the dose-response curve was sleeper compared with the case of the nonpegylated form of this molecule. Five consecutive injections with PEG- rHuMGDF caused a dose-dependent increase in peripheral platelet counts with a peak on day 8. There was a dose-dependent rise in platelet counts on day 8 at daily doses from 0.333 to 30 μg/kg. Intermediate doses of PEG-rHuMGDF (1.111 to 10 μg/kg/day) caused a significant decrease in mean platelet volume, and conversely, higher doses of PEG-rHuMGDF (30 to 270 μg/kg/day) induced a dose-dependent increase in mean platelet volume. There was a dose-dependent decrease in hemoglobin concentration with a minimum on day 8 but no significant reduction in reticulocyte counts following PEG-rHuMGDF administration. White blood cell counts were unchanged by PEG-rHuMGDF treatment. Marrow megakaryocyte size enlarged in 1.5-fold and the number of marrow megakaryocytes increased to sixfold by consecutive administration of PEG-rHuMGDF at 30 μg/kg/day. A twofold increase in the number of marrow megakaryocytic progenitor cells (colony-forming units-megakaryocyte) was also observed. Marrow erythroid progenitor (colony-forming units-erythroid) counts decreased but splenic colony-forming units-erythroid, marrow and splenic erythro/myeloid progenitor cell counts, and splenic granulocyte/macrophage progenitor cell counts increased with PEG-rHuMGDF treatment. Marrow and splenic erythroid burst-forming cells were unchanged. These results indicate that PEG-rHuMGDF, a truncated molecule of thrombopoietin, is a potent stimulator for megakaryopoiesis and thrombopoiesis, and also affects the development of other hematopoietic cells in normal mice.

Original languageEnglish
Pages (from-to)651-660
Number of pages10
JournalStem Cells
Volume14
Issue number6
Publication statusPublished - 1996 Nov
Externally publishedYes

Fingerprint

Hematopoiesis
Bone Marrow
Megakaryocytes
Mean Platelet Volume
Thrombopoietin
Erythroid Precursor Cells
Platelet Count
Stem Cells
Cell Count
polyethylene glycol-recombinant human megakaryocyte growth and development factor
Thrombopoiesis
Myeloid Progenitor Cells
Reticulocyte Count
Granulocyte-Macrophage Progenitor Cells
Leukocyte Count
Hemoglobins
Blood Platelets
Injections

Keywords

  • Megakaryocyte
  • Megakaryocyte growth and development factor (MGDF)
  • Megakaryocytic progenitor
  • Platelet
  • Thrombopoietin (TPO)

ASJC Scopus subject areas

  • Cell Biology

Cite this

Kabaya, K., Akahori, H., Shibuya, K., Nitta, Y., Ida, M., Kusaka, M., ... Miyazaki, H. (1996). In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells, 14(6), 651-660.

In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. / Kabaya, Koji; Akahori, Hiromichi; Shibuya, Kazunori; Nitta, Yuko; Ida, Masumi; Kusaka, Masaru; Kato, Takashi; Miyazaki, Hiroshi.

In: Stem Cells, Vol. 14, No. 6, 11.1996, p. 651-660.

Research output: Contribution to journalArticle

Kabaya, K, Akahori, H, Shibuya, K, Nitta, Y, Ida, M, Kusaka, M, Kato, T & Miyazaki, H 1996, 'In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice', Stem Cells, vol. 14, no. 6, pp. 651-660.
Kabaya K, Akahori H, Shibuya K, Nitta Y, Ida M, Kusaka M et al. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells. 1996 Nov;14(6):651-660.
Kabaya, Koji ; Akahori, Hiromichi ; Shibuya, Kazunori ; Nitta, Yuko ; Ida, Masumi ; Kusaka, Masaru ; Kato, Takashi ; Miyazaki, Hiroshi. / In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. In: Stem Cells. 1996 ; Vol. 14, No. 6. pp. 651-660.
@article{f9f73260b3c54b2bb65723fce8d61510,
title = "In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice",
abstract = "The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human thrombopoietin modified with polyethylene glycol, were investigated in normal Balb/c mice. PEG-rHuMGDF was more potent in producing platelets and the dose-response curve was sleeper compared with the case of the nonpegylated form of this molecule. Five consecutive injections with PEG- rHuMGDF caused a dose-dependent increase in peripheral platelet counts with a peak on day 8. There was a dose-dependent rise in platelet counts on day 8 at daily doses from 0.333 to 30 μg/kg. Intermediate doses of PEG-rHuMGDF (1.111 to 10 μg/kg/day) caused a significant decrease in mean platelet volume, and conversely, higher doses of PEG-rHuMGDF (30 to 270 μg/kg/day) induced a dose-dependent increase in mean platelet volume. There was a dose-dependent decrease in hemoglobin concentration with a minimum on day 8 but no significant reduction in reticulocyte counts following PEG-rHuMGDF administration. White blood cell counts were unchanged by PEG-rHuMGDF treatment. Marrow megakaryocyte size enlarged in 1.5-fold and the number of marrow megakaryocytes increased to sixfold by consecutive administration of PEG-rHuMGDF at 30 μg/kg/day. A twofold increase in the number of marrow megakaryocytic progenitor cells (colony-forming units-megakaryocyte) was also observed. Marrow erythroid progenitor (colony-forming units-erythroid) counts decreased but splenic colony-forming units-erythroid, marrow and splenic erythro/myeloid progenitor cell counts, and splenic granulocyte/macrophage progenitor cell counts increased with PEG-rHuMGDF treatment. Marrow and splenic erythroid burst-forming cells were unchanged. These results indicate that PEG-rHuMGDF, a truncated molecule of thrombopoietin, is a potent stimulator for megakaryopoiesis and thrombopoiesis, and also affects the development of other hematopoietic cells in normal mice.",
keywords = "Megakaryocyte, Megakaryocyte growth and development factor (MGDF), Megakaryocytic progenitor, Platelet, Thrombopoietin (TPO)",
author = "Koji Kabaya and Hiromichi Akahori and Kazunori Shibuya and Yuko Nitta and Masumi Ida and Masaru Kusaka and Takashi Kato and Hiroshi Miyazaki",
year = "1996",
month = "11",
language = "English",
volume = "14",
pages = "651--660",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice

AU - Kabaya, Koji

AU - Akahori, Hiromichi

AU - Shibuya, Kazunori

AU - Nitta, Yuko

AU - Ida, Masumi

AU - Kusaka, Masaru

AU - Kato, Takashi

AU - Miyazaki, Hiroshi

PY - 1996/11

Y1 - 1996/11

N2 - The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human thrombopoietin modified with polyethylene glycol, were investigated in normal Balb/c mice. PEG-rHuMGDF was more potent in producing platelets and the dose-response curve was sleeper compared with the case of the nonpegylated form of this molecule. Five consecutive injections with PEG- rHuMGDF caused a dose-dependent increase in peripheral platelet counts with a peak on day 8. There was a dose-dependent rise in platelet counts on day 8 at daily doses from 0.333 to 30 μg/kg. Intermediate doses of PEG-rHuMGDF (1.111 to 10 μg/kg/day) caused a significant decrease in mean platelet volume, and conversely, higher doses of PEG-rHuMGDF (30 to 270 μg/kg/day) induced a dose-dependent increase in mean platelet volume. There was a dose-dependent decrease in hemoglobin concentration with a minimum on day 8 but no significant reduction in reticulocyte counts following PEG-rHuMGDF administration. White blood cell counts were unchanged by PEG-rHuMGDF treatment. Marrow megakaryocyte size enlarged in 1.5-fold and the number of marrow megakaryocytes increased to sixfold by consecutive administration of PEG-rHuMGDF at 30 μg/kg/day. A twofold increase in the number of marrow megakaryocytic progenitor cells (colony-forming units-megakaryocyte) was also observed. Marrow erythroid progenitor (colony-forming units-erythroid) counts decreased but splenic colony-forming units-erythroid, marrow and splenic erythro/myeloid progenitor cell counts, and splenic granulocyte/macrophage progenitor cell counts increased with PEG-rHuMGDF treatment. Marrow and splenic erythroid burst-forming cells were unchanged. These results indicate that PEG-rHuMGDF, a truncated molecule of thrombopoietin, is a potent stimulator for megakaryopoiesis and thrombopoiesis, and also affects the development of other hematopoietic cells in normal mice.

AB - The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human thrombopoietin modified with polyethylene glycol, were investigated in normal Balb/c mice. PEG-rHuMGDF was more potent in producing platelets and the dose-response curve was sleeper compared with the case of the nonpegylated form of this molecule. Five consecutive injections with PEG- rHuMGDF caused a dose-dependent increase in peripheral platelet counts with a peak on day 8. There was a dose-dependent rise in platelet counts on day 8 at daily doses from 0.333 to 30 μg/kg. Intermediate doses of PEG-rHuMGDF (1.111 to 10 μg/kg/day) caused a significant decrease in mean platelet volume, and conversely, higher doses of PEG-rHuMGDF (30 to 270 μg/kg/day) induced a dose-dependent increase in mean platelet volume. There was a dose-dependent decrease in hemoglobin concentration with a minimum on day 8 but no significant reduction in reticulocyte counts following PEG-rHuMGDF administration. White blood cell counts were unchanged by PEG-rHuMGDF treatment. Marrow megakaryocyte size enlarged in 1.5-fold and the number of marrow megakaryocytes increased to sixfold by consecutive administration of PEG-rHuMGDF at 30 μg/kg/day. A twofold increase in the number of marrow megakaryocytic progenitor cells (colony-forming units-megakaryocyte) was also observed. Marrow erythroid progenitor (colony-forming units-erythroid) counts decreased but splenic colony-forming units-erythroid, marrow and splenic erythro/myeloid progenitor cell counts, and splenic granulocyte/macrophage progenitor cell counts increased with PEG-rHuMGDF treatment. Marrow and splenic erythroid burst-forming cells were unchanged. These results indicate that PEG-rHuMGDF, a truncated molecule of thrombopoietin, is a potent stimulator for megakaryopoiesis and thrombopoiesis, and also affects the development of other hematopoietic cells in normal mice.

KW - Megakaryocyte

KW - Megakaryocyte growth and development factor (MGDF)

KW - Megakaryocytic progenitor

KW - Platelet

KW - Thrombopoietin (TPO)

UR - http://www.scopus.com/inward/record.url?scp=0029853230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029853230&partnerID=8YFLogxK

M3 - Article

C2 - 8948023

AN - SCOPUS:0029853230

VL - 14

SP - 651

EP - 660

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 6

ER -